Home
/
RELIGION & LIBERTY ONLINE
/
Why cheap drugs from Canada won’t reduce U.S. Drug prices
Why cheap drugs from Canada won’t reduce U.S. Drug prices
Nov 24, 2025 8:36 PM

If you suffer from acid reflux, your doctor may prescribe Nexium. But at $9 a pill, the price is enough to give you a worse case of heartburn.

That’s the lowest price in the U.S. If you live in Canada, though, you can get the drug for less than a $1 a pill.

This price disparity leads many politicians to think the solution is obvious: Americans should just buy drugs from Canada or other countries where they are cheaper.

Its plan supported by economic liberals like President Trump and Bernie Sanders. Several years ago Sen. Amy Klobuchar (D-Minn.) and John McCain (R-Az.) twice introduced legislation to allow Americans to order up to a 90-day supply of medicines from a licensed Canadian pharmacy. The Democratic Party even made it a part of their party platform in 2016.

If this seems too easy, it’s because it’s an economically ignorant idea. Writing in the Harvard Business Review a few years ago, Rafi Mohammed explained why this strategy won’t work:

The reason why pharmaceutical prices are relatively high in the U.S. is panies employ mon strategy called differential pricing. This strategy targets specific segments with different prices. So instead of having the same price for everyone, the goal is to tailor the “right” price to various segments. Movie theaters, for instance, use differential pricing by offering lower prices to students and seniors. The assumption is students and seniors are sensitive to price, sooffering targeted discounts to them is profitable. As a result, moviegoers seated next to each other often have paid different prices.

For differential pricing to be profitable, targeted segments have to be easily identifiable, and,most importantly, arbitrage cannot occur. By arbitrage, I mean those who receive discounts don’t resell to customers who are currently paying more. This strategy works well at cinemas: it’s easy to identify seniors/students, and since tickets are sold individually at the door, enterprising seniors/students typically aren’t reselling discounted tickets for a profit.

Why are drug prices so much higher in the U.S.? The answer is straightforward: most countries regulate prices or have a single-payer health care system, in which the government pays for citizens’ health care costs. In a single-payer system, the government buys all a country’s pharmaceuticals, and it has leverage in “take it or leave it” negotiations with panies.

Mohammed’s explanation is helpful, but it’s also plete. What he doesn’t mention is the reason whythe price differential for drugs can work: because expensive medicines in the U.S. subsidize the creation of drugs for the entire world.

According to the pharmaceutical giant Eli Lilly, the average cost to discover and develop a new drug is between $800 million to $1.2 billion, and the average length of time from discovery to patient is 10 to 15 years.

If a product costs $1 billion to produce and bring to market, that is the initial fixed cost. Think of it this way: the initial cost to produce the very first Nexium pill is roughly $1 billion. But once that first pill is created, the cost to produce the second, third, fourth, . . . hundred thousandth pill is very low. But if the initial fixed cost cannot be recovered, then pany will lay out the money and spend a decade or more creating the product. New medications will simply not exist.

This point should be obvious—and yet it is widely overlooked and ignored. People see a drug, like Nexium, and forget that it only exists because a pany believed it could recoup the cost of research and development and make a profit by selling the medicine. But how is pany able to earn back the initial billion dollar fixed costs? By charging some buyer—whether a government, HMO, pany or individual—a price that will cover the initial fixed costs.

Once that fixed costs of creating the drug is covered, though, the price can be reduced since the remaining variable costs (e.g., the cost to produce each individual pill) tend to be relatively low. And this brings us to why you, as an American, pay a higher price for a drug that Canadians and Europeans get much cheaper.

To make it easier to understand, let’s imagine that a medicine is created to cure a single disease in three patients living in America, Canada, and France. Now let’s say that the patient in America pays all of the fixed cost ($1 billion), plus the variable cost for one pill (50 cents), plus 50 cents in profit for pany. In total, the American ends up paying $1,000,000,001 for a single pill.

The pany is happy because they recouped their costs and made a profit (50 cents). Canada and France say that they too want to buy the drug, but they will pay only $1. The pany agrees to sell the pill for $1 to both Canada and France because an additional $1 profit is better than $0 in additional profit. Everyone is happy.

Well, maybe not everyone. The American may say that it wasn’t fair for them to pay all the fixed costs —and they’d be right. In our example, Canada and France are free riders that are able to take advantage of the lower costs only because the Americans have already paid the exorbitant fixed costs. The American subsidized the cost of the drug for the patients in the other countries.

This is exactly what happens with most drugs. Very few new medicines are produced in countries that have government restrictions on drug prices. And almost no new drugs would be produced if all countries had government restrictions on drug prices. Without the willingness of the United States to pay the higher prices, the drugs would never e into existence. Countries like Canada and France are like roommates who let you pay full price for a pizza but expect you to give them a slice in exchange for a few pennies they found in the couch.

Which brings us back to the “reimport the drugs” strategy. The reason this approach won’t work is because once Americans stop subsidizing the drugs for the rest of the world, panies will not be able to recoup their costs for R&D. paniessimply won’t be able to afford to create innovative new medicines. That makes everyone worse off than before.

Ultimately, socialized medicine—in the form of government-imposed drug pricing—doesn’t work for the same reason Margaret Thatcher said socialist governments don’t work: “They always run out of other people’s money.”

Comments
Welcome to mreligion comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
RELIGION & LIBERTY ONLINE
Material Poverty, Spiritual Poverty, and Tony Campolo
During my seminary days at Asbury Theological Seminary, Tony Campolo spoke at a chapel service and offered a litany of denunciations of greed and corporate America. However, one thing he said especially caught the attention of a professor of mine. During his talk, Campolo equated material poverty with spiritual righteousness. Later in the day during class, while the rest of the campus was still gushing over Campolo’s visit, the professor rebuked Campolo rather harshly. He said he stood with him...
The Rich Young Man: The Law Versus Privilege
Below is the full-length version of “The Rich Young Man: The Law Versus Privilege,” an essay published in the winter 2011 Religion & Liberty. John Kelly’s essay was shortened because of space limitations for the print issue. He was passionate about sharing the full version, which he edited himself for readers of the PowerBlog. Mr. Kelly, a financial advisor, also authored a piece in 2004 for Religion & Liberty titled “The Tithe: Land Rent to God.” — — — —...
We Need a Place not a Prophet
The always challenging Peter Berger has a fascinating post up on the history of Bad Boll Academy: The Academy was to have two goals: to train the laity for service to society; and to be a place for free and open discussion about problems facing the society, especially between groups (such as management and labor) which did not normally meet under such conditions.This second goal was the most innovative. The Academy was not to be a place for evangelism. Nor...
Surging Food Prices
As a follow up to recent blog posts (here, here, and here) where rising food prices have been discussed, the most current numbers have been released. What many of us already know from visits to the grocery store is that food prices have increased dramatically. Food prices rose by 3.9 percent in the month of February, making this the largest increase since November of 1974. An article from the Associated Press explains the rise in food prices while also showing...
Gritty Entrepreneurship
A piece in Fast Company, “Why True Grit Matters in the Face of Adversity,” focuses on the virtue of “grit” in various fields, including public lobbying and business. Dan and Chip Heath distinguish “true grit” from “hard work,” as they write: Grit is not synonymous with hard work. It involves a certain single-mindedness. An ungritty prison inmate will formulate a new plan of escape every month, but a gritty prison inmate will tunnel his way out one spoonful of concrete...
Audio: Ballor and Strauss on Intergenerational Justice
At long last, here’s the audio from our munity event. On March 10 at Derby Station in East Grand Rapids, Acton hosted an open mic discussion on “A Call for Intergenerational Justice: A Christian Proposal for the American Debt Crisis” featuring Gideon Strauss of The Center for Public Justice – one of the drafters of the statement – and Acton’s own Jordan Ballor. A mea culpa – in my effort to make sure that the equipment used to record the...
The Orthodox Church in the Public Square
Metropolitan JonahJulia Duin, a veteran religion reporter, has written a profile of the embattled leader of the Orthodox Church in America, Metropolitan Jonah, for the Washington Post weekend edition. She does an admirable and fair job of not only telling us about this American-born bishop but explaining why his short tenure has sparked so much controversy within the various Orthodox jurisdictions in the United States. (Let me bring to your attention, right away, that Jonah is our plenary speaker on...
Five Things
It’s been awhile since I’ve done a summary post of this kind, but there’s been a fair number of things of interest over the last week or so that are worthy of a quick highlight. So here’s an edition of the aptly named “Five Things” (HT): Carl Trueman reflects on his visit to the Acton Institute. Concerned about how his Republocrat credentials e across, Trueman says, “Despite my fears that I might be heavily outgunned at Acton, the seminar actually...
Event: Catholic Education Foundation, March 25 in New York
From our friends at CEF in Rochester, N.Y.: The Catholic Education Foundation, an mitted to ensuring a bright and significant future for Catholic high schools in the United States, will be hosting its biennial, day-long celebration of Catholic secondary schools on March 25 in New York City. The theme of the event will be Catholic Education – Holistic Education: A Tribute to Pope John Paul II, Promoter of Catholic Schools. Presenters will include Sr. Mary Thomas, O.P., Principal, St. Cecilia...
Green Patriarch: No Nukes
With the terrible human toll from Japan’s earthquake and tsunami catastrophe only now prehended, and the grave follow on crisis at the country’s nuclear power plants unfolding by the hour, the anti-nuclear power crowd has already begun issuing statements such as the one Greenpeace put out saying that “nuclear power cannot ever be safe.” Predictably, reports Geoffrey Lean in the Telegraph, “battle lines” are being drawn: On Saturday, some 50,000 anti-nuclear protesters formed a 27-mile human chain from Germany’s Neckarwestheim...
Related Classification
Copyright 2023-2025 - www.mreligion.com All Rights Reserved